PT - JOURNAL ARTICLE AU - Emily Littlejohn TI - Keeping lupus patients on hydroxychloroquine during the COVID-19 pandemic AID - 10.3949/ccjm.87a.ccc023 DP - 2020 May 11 TA - Cleveland Clinic Journal of Medicine PG - ccc023 4099 - http://www.ccjm.org/content/early/2020/05/06/ccjm.87a.ccc023.short 4100 - http://www.ccjm.org/content/early/2020/05/06/ccjm.87a.ccc023.full AB - Hydroxychloroquine (HCQ) is in short supply as a result of the coronavirus disease 2019 (COVID-19) pandemic, presenting a challenge to rheumatologists to ensure their patients with systemic lupus erythematosus (SLE) continue to take this essential drug. HCQ is the only SLE treatment shown to increase survival and any change in the HCQ regimen is potentially dangerous. Changes in the HCQ regimen should be made jointly with the patient after a discussion of the available evidence and expert opinion and the patient’s preferences. Providers need to make thoughtful, informed decisions in this time of medication shortage.